MaxCyte, Inc. (MXCT)

Market Cap	102.69M -37.5%
Revenue (ttm)	31.05M -13.2%
Net Income	-35.64M
EPS	-0.33
Shares Out	103.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	150,123
Open	1.0100
Previous Close	1.0100
Day's Range	0.9722 - 1.0100
52-Week Range	0.6434 - 1.8650
Beta	1.49
Analysts	Strong Buy
Price Target	4.11 (+313.07%)
Est. Earnings	Nov 4, 2026

About MXCT

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engi...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 91
• Stock Exchange: Nasdaq
• Ticker Symbol: MXCT
• Website: https://www.maxcyte.com

Financial Performance

In 2025, MaxCyte's revenue was $33.03 million, a decrease of -14.50% compared to the previous year's $38.63 million. Losses were -$44.63 million, 8.71% more than in 2024.

Analyst Summary

According to 6 analysts, the average rating for MXCT stock is "Strong Buy." The 12-month stock price target is $4.11, which is an increase of 313.07% from the latest price.

Price Target

$4.11

(313.07% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 13, 2026

Data Sources Report a data error